Julia Foldi MD and colleagues from the Lee-Oesterreich laboratory collaborated with Natera Inc to report on retrospective analysis of real-world data in 66 patients with metastatic ILC using a clinically validated, personalized, tumor-informed ctDNA assay (Signatera). Serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring.
https://pubmed.ncbi.nlm.nih.gov/40324116
